Spero Therapeutics, Inc.
SPRO
$1.17
-$0.02-1.68%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 258.00K | 41.30M | 5.44M | 14.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 258.00K | 41.30M | 5.44M | 14.19M |
| Cost of Revenue | 3.43M | 2.91M | -27.28M | 8.60M | 10.67M |
| Gross Profit | -3.43M | -2.65M | 109.88M | -3.16M | 3.52M |
| SG&A Expenses | 6.49M | 4.89M | 4.30M | 4.17M | 5.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.93M | 7.80M | 9.89M | 12.77M | 16.55M |
| Operating Income | -9.93M | -7.54M | 31.41M | -7.33M | -2.36M |
| Income Before Tax | -9.55M | -7.20M | 31.78M | -7.38M | -1.70M |
| Income Tax Expenses | -- | -- | 261.00K | -- | -- |
| Earnings from Continuing Operations | -9.55M | -7.20M | 31.52M | -7.38M | -1.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.55M | -7.20M | 31.52M | -7.38M | -1.70M |
| EBIT | -9.93M | -7.54M | 31.41M | -7.33M | -2.36M |
| EBITDA | -- | -- | 31.41M | -7.33M | -2.36M |
| EPS Basic | -0.16 | -0.13 | 0.56 | -0.13 | -0.03 |
| Normalized Basic EPS | -0.10 | -0.08 | 0.35 | -0.08 | -0.02 |
| EPS Diluted | -0.16 | -0.13 | 0.54 | -0.13 | -0.03 |
| Normalized Diluted EPS | -0.10 | -0.08 | 0.33 | -0.08 | -0.02 |
| Average Basic Shares Outstanding | 57.97M | 57.28M | 56.02M | 56.28M | 56.03M |
| Average Diluted Shares Outstanding | 57.97M | 57.28M | 59.37M | 56.28M | 56.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |